Brain metastasis of breast tumors and blood brain barrier;Métastases cérébrales des cancers du sein et barrière hématoméningée

Bulletin du Cancer

Volumn 98, Issue 4, 2011, Pages 385-389

  Diéras, Véronique ^a   Pierga, Jean Yves ^a,b  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Angiogenesis; Brain metastasis; Brain blood barrier; Breast cancer; HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER INCIDENCE; CANCER MODEL; CANCER SURVIVAL; LYMPHOMA; MOLECULAR PATHOLOGY; ONCOGENE NEU; PREVALENCE; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER;

EID: 79957547465     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1336     Document Type: Review

References (31)

1. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17 : 935-44. (Pubitemid 43778983)
2. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107 : 696-704. (Pubitemid 44232661)
3. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 2008; 19 : 1561-5.
4. Gabos Z, Sinha R, Hanson J, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006; 24 : 5658-63. (Pubitemid 46631306)
5. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12 : 895-904. (Pubitemid 44175140)
6. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3 : 537-49. (Pubitemid 36808649)
7. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008; 359 : 2814-23.
8. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9 : 274-84.
9. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436 : 518-24. (Pubitemid 41112921)
10. Lu W, Bucana CD, Schroit AJ. Pathogenesis and vascular integrity of breast cancer brain metastasis. Int J Cancer 2007; 120 : 1023-6. (Pubitemid 46214301)
11. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3 : 453-8. (Pubitemid 37328849)
12. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22 : 3608-17. (Pubitemid 41103668)
13. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007; 25 : 2295-305. (Pubitemid 46954658)
14. Tosoni A, Franceschi E, Brandes AA. Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome? Crit Rev Oncol Hematol 2008; 68 : 212-21.
15. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007; 25 : 2306-12.
16. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002; 3 : 53-7. (Pubitemid 34121146)
17. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006; 12 : 5018-22. (Pubitemid 44453326)
18. Leenders WP, Kusters B, Verrijp K, et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 2004; 10 : 6222-30. (Pubitemid 39287530)
19. Kim LS, Huang S, Lu W, Lev DC, Price JE. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 2004; 21 : 107-18. (Pubitemid 38988084)
20. Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS. The biology of metastasis to a sanctuary site. Clin Cancer Res 2007; 13 : 1656-62. (Pubitemid 46957363)
21. Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459 : 1005-9.
22. Yonemori K, Tsuta K, Ono M, et al. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 2010; 116 : 302-8.
23. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumabbased therapy for metastatic breast carcinoma. Cancer 2003; 97 : 2972-7. (Pubitemid 36676250)
24. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91 : 639-43. (Pubitemid 39141617)
25. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006; 15 : 219-25.
26. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004; 101 : 810-6. (Pubitemid 39030939)
27. Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004; 40 : 379-82. (Pubitemid 38121275)
28. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007; 13 : 1648-55. (Pubitemid 46952930)
29. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008; 100 : 1092-103.
30. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355 : 2733-43. (Pubitemid 46021510)
31. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15 : 1452-9.